Ortin Global Ltd stock analysis
Want to see IN:ORTINGLOBE full AI Analyst Report?
Ortin Global Ltd (ORTINGLOBE) Stock Price & Analysis
ORTINGLOBE Stock Chart & Stats
- Day’s Range
- INR 12.76 - INR 14.57
- 52-Week Range
- INR 11.36 - INR 21.15
- Previous Close
- INR 13.52
- Volume
- N/A
- Average Volume (3M)
- 1,253
- Market Cap
- INR 105.55M
- Enterprise Value
- INR 129.39M
- Total Cash (Recent Filing)
- INR 6.06M
- Total Debt (Recent Filing)
- INR 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.44
- Next Earnings
- Feb 16, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
FY2026 Revenue Growth
The sharp FY2026 revenue increase indicates that the company retained some ability to expand its top line despite difficult operating results. If this growth can be sustained and converted into healthier gross margins, it could provide a foundation for improving scale and future earnings quality.
Positive Shareholders' Equity
Positive equity provides a remaining balance-sheet buffer against operating losses and obligations, giving the company more resilience than an entity with a deficit position. This cushion may support continued operations while management works to stabilize profitability and reduce financial risk.
Free Cash Flow Improvement
The move in free cash flow from negative in FY2025 to break-even in FY2026 represents an improvement in cash retention. Although operating cash flow remained negative, reaching break-even reduces the immediate pace of cash erosion and could become constructive if operating cash generation also improves.
Bears Say
Severe Margin And Earnings Losses
Profitability has deteriorated to a level where revenue growth is not translating into economic value: gross profit is negative and operating and net losses are exceptionally large. Such severe margin weakness threatens the sustainability of the business and makes a near-term earnings recovery dependent on major cost or pricing improvements.
Persistent Operating Cash Burn
Repeatedly negative operating cash flow shows that the core business is consuming cash rather than funding its own activities. This weakens financial flexibility, increases reliance on external funding, and makes it harder for the company to invest in growth or withstand further operating setbacks.
Materially Higher Leverage
The substantial increase in debt relative to equity reduces balance-sheet flexibility while the company is already reporting sizable losses. Higher leverage can increase refinancing and solvency pressure, leaving fewer options to fund operations and raising the consequences of any continued weakness in performance.
Ortin Global Ltd News
ORTINGLOBE FAQ
What was Ortin Global Ltd’s price range in the past 12 months?
What is Ortin Global Ltd’s market cap?
When is Ortin Global Ltd’s upcoming earnings report date?
How were Ortin Global Ltd’s earnings last quarter?
Is Ortin Global Ltd overvalued?
Does Ortin Global Ltd pay dividends?
What is Ortin Global Ltd’s EPS estimate?
How many shares outstanding does Ortin Global Ltd have?
What happened to Ortin Global Ltd’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ortin Global Ltd?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ortin Global Ltd
Ortin Global Ltd., established in 1986 and headquartered in Hyderabad, India, is an Indian enterprise specializing in the manufacturing and trading of pharmaceuticals, drugs, and their intermediates. The company, formerly known as Ortin Laboratories Limited until its name change in June 2024, offers an extensive portfolio of pharmaceutical formulations available as tablets, capsules, syrups, and dry powders. These products address a wide spectrum of therapeutic areas, including anti-diabetics, anti-allergics, cardiovascular conditions, sedatives, anti-helminthics, analgesics, antipyretics, various antibiotics (quinolones, penicillins, cephalosporins, macrolides), antifungals, chemotherapeutics, antacids, anti-ulcerants, anti-spasmodics, calcium and iron supplements, anti-arthritic drugs, protein supplements, enzymes, vitamins, as well as psychiatry, appetite stimulant, gynecological, and anti-retroviral medications. Beyond finished dosage forms, Ortin Global produces active pharmaceutical ingredient (API) intermediates for anti-retroviral, anti-diabetic, analgesic, antipyretic, antibiotic, antifungal, anti-ulcerant, and anti-malarial applications. Its manufacturing capabilities also extend to fine chemicals, Grignard products, and alkali metal compounds. The company provides a range of specialized services, including process development, characterization of processes and products, analytical research and development, and assay development. It also offers R&D for new formulation brands and diagnostic services, focusing on the creation of rapid flow kits, assays, and reagents. Additionally, Ortin Global secures long-term contracts for manufacturing intermediates and developing new APIs, functions as a merchant exporter of finished pharmaceutical formulations, and holds interests in real estate.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Sanka Murali Krishna Murthy
- Employees
- 8
- Website
- www.ortinlabsindia.com
- Address
- D. No: 1-8-305, Ground Floor, Hyderabad, TS, 500020, IN
Ortin Global Ltd (ORTINGLOBE) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:BIOFILCHEMBiofil Chemicals & Pharmaceuticals Ltd. | ||
| IN:LASALasa Supergenerics Ltd. | ||
| IN:MANGALAMMangalam Drugs & Organics Ltd. | ||
| IN:PARPar Drugs and Chemicals Limited | ||
| IN:VIVIMEDLABVivimed Labs Limited |





